I am a board-certified radiation oncologist specializing in the treatment of gastrointestinal and lung cancers. These diseases are often best treated by a combination of therapies, so I work closely with medical and surgical oncologists to deliver coordinated, state-of-the-art care. I have experience with advanced techniques such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic radiation therapy, which can be used to maximize the effectiveness of radiation while reducing toxicity.
It is important to me that each patient understands his or her disease and its treatment, so I am committed to being friendly, accessible, and clear to anyone who comes under my care.
- Clinical Expertise: Gastrointestinal Cancer; Lung Cancer; Anal Cancer; Pancreatic Cancer; Gastric Cancer
- Languages Spoken: English
- Education: MD, Harvard Medical School
- Residencies: Virginia Mason Medical Center; Memorial Sloan Kettering Cancer Center
- Board Certifications: Radiation Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Abraham J. Wu
- A Phase I Study of High-Dose-Rate Brachytherapy plus Chemotherapy in Patients with Recurrent Rectal or Anal Cancer
- A Phase III Study of Chemotherapy with Either Proton Therapy or Conventional Photon Radiation Therapy to Treat Inoperable Stage II-IIIB Non-Small Cell Lung Cancer
- A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Pancreatic Cancer
Clinical Trials Co-Investigated by Abraham J. Wu
- A Phase I Study of Stereotactic Body Radiation Therapy for Inoperable Locally Advanced Non-Small Cell Lung Cancer
- A Phase II Study of Chemotherapy and Chemoradiation Followed by Surgery or Non-Operative Management in Patients with Stage II or III Rectal Cancer
- A Pilot Study of Erlotinib plus Local Treatment for Lung Adenocarcinoma that Has Spread to Multiple Sites
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more